Skip to main content
Top
Published in: The Journal of Headache and Pain 1/2015

Open Access 01-12-2015 | Research article

Clinical and Demographical Characteristics of Patients with Medication Overuse Headache in Argentina and Chile: Analysis of the Latin American Section of COMOESTAS Project

Authors: Beatriz Shand, Maria Teresa Goicochea, Raul Valenzuela, Ricardo Fadic, Rigmor Jensen, Cristina Tassorelli, Giuseppe Nappi,  the COMOESTAS CONSORTIUM

Published in: The Journal of Headache and Pain | Issue 1/2015

Login to get access

Abstract

Background

Data on the characteristics of Medication Overuse Headache (MOH) in Latin American (LA) are scarce. Here we report the demographic and clinical features of the MOH patients from Argentina and Chile enrolled in the multinational COMOESTAS project in the period 2008–2010.

Methods

The LA population was formed by 240 MOH subjects, 110 from Chile and 130 from Argentina, consecutively attending the local headache centres. In each centre, specifically trained neurologist interviewed and confirmed the diagnosis according to the ICHD-II criteria. A detailed history was collected on an electronic patient record form.

Results

The mean patient age was 38.6 years, with a female/male ratio of 8:2. The mean time since onset of the primary headache was 21 years, whereas duration of MOH was 3.9 years. The primary headache was migraine without aura in 77.5 % and migraine with aura in 18.8 %. Forty two % of the patients self-reported emotional stress associated with the chronification of headache; 43.8 % reported insomnia. The most overused medications were acute drug combinations containing ergotamine (70 %), NSAIDs (33.8 %) and triptans (5.4 %).

Conclusion

Though little described, MOH is present also in LA, where it affects mostly women, in the most active decades of life. Some differences emerge as regards the demographic and clinical characteristics of MOH in this population as compared to Europe or Northern America. What seems more worrying about MOH in Argentina and Chile is that most patients overuse ergotamine, a drug that may cause serious adverse events when used chronically. These findings once more underscore the importance of properly diagnose and treat MOH.
Literature
1.
go back to reference Munskgaard S, Jensen R (2014) Medication overuse headache. Headache 54(7):1251–1257CrossRef Munskgaard S, Jensen R (2014) Medication overuse headache. Headache 54(7):1251–1257CrossRef
2.
go back to reference Silberstein S (2003) Chronic daily headache. Continuum: Headache Update 9:121–143 Silberstein S (2003) Chronic daily headache. Continuum: Headache Update 9:121–143
3.
go back to reference Zeeberg P, Olesen J, Jensen R (2005) Efficacy of multidisciplinary treatment in a tertiary referral headache centre. Cephalalgia 25(12):1159–1167CrossRefPubMed Zeeberg P, Olesen J, Jensen R (2005) Efficacy of multidisciplinary treatment in a tertiary referral headache centre. Cephalalgia 25(12):1159–1167CrossRefPubMed
4.
go back to reference Diener HC, Limmroth V (2004) Medication-overuse headache: a worldwide problem. Lancet Neurol 3(8):475–483CrossRefPubMed Diener HC, Limmroth V (2004) Medication-overuse headache: a worldwide problem. Lancet Neurol 3(8):475–483CrossRefPubMed
5.
go back to reference Haag G, Baar H, Grotemeyer KH et al. (1999) Prophylaxis and treatment of drug-induced persistent headache. Therapy recommendation of the German Society for Migraine and Headache. Schmerz 13(1):52–57CrossRefPubMed Haag G, Baar H, Grotemeyer KH et al. (1999) Prophylaxis and treatment of drug-induced persistent headache. Therapy recommendation of the German Society for Migraine and Headache. Schmerz 13(1):52–57CrossRefPubMed
6.
go back to reference Kristoffersen E, Lundqvist C (2014) Medication-overuse headache: a review (2014). J Pain Res 26:367–378CrossRef Kristoffersen E, Lundqvist C (2014) Medication-overuse headache: a review (2014). J Pain Res 26:367–378CrossRef
7.
go back to reference Ghiotto N, Sances G, Galli F et al. (2009) Medication overuse headache and applicability of the ICHD-II diagnostic criteria: 1-year follow-up study (CARE I protocol). Cephalalgia 29:233–243CrossRefPubMed Ghiotto N, Sances G, Galli F et al. (2009) Medication overuse headache and applicability of the ICHD-II diagnostic criteria: 1-year follow-up study (CARE I protocol). Cephalalgia 29:233–243CrossRefPubMed
8.
9.
go back to reference Hagen K, Linde M, Steiner T et al (2012) Risk factor for medication-overuse headache: an 11 year- follow-up study. The Nord- Trondelag Health Studies. Pain 153:56–61CrossRefPubMed Hagen K, Linde M, Steiner T et al (2012) Risk factor for medication-overuse headache: an 11 year- follow-up study. The Nord- Trondelag Health Studies. Pain 153:56–61CrossRefPubMed
10.
go back to reference Zebenholzer K, Andree C, Lechner A, Broessner G, Lampl C, Luthringshausen G, Wuschitz A, Obmann SM, Berek K, Wöber C (2015) Prevalence, management and burden ofepisodic and chronic headaches--a cross-sectional multicentre study in eightAustrian headache centres. J Headache Pain 16:531CrossRefPubMed Zebenholzer K, Andree C, Lechner A, Broessner G, Lampl C, Luthringshausen G, Wuschitz A, Obmann SM, Berek K, Wöber C (2015) Prevalence, management and burden ofepisodic and chronic headaches--a cross-sectional multicentre study in eightAustrian headache centres. J Headache Pain 16:531CrossRefPubMed
11.
go back to reference Westergaard ML, Glümer C, Hansen EH, Jensen RH (2014) Prevalence of chronic headache with and without medication overuse: associations with socioeconomic position and physical and mental health status. Pain 155:2005–2013CrossRefPubMed Westergaard ML, Glümer C, Hansen EH, Jensen RH (2014) Prevalence of chronic headache with and without medication overuse: associations with socioeconomic position and physical and mental health status. Pain 155:2005–2013CrossRefPubMed
12.
go back to reference Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Barré J, Andrée C (2014) The impact ofheadache in Europe: principal results of the Eurolight project. J Headache Pain 15:31PubMedCentralCrossRefPubMed Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Barré J, Andrée C (2014) The impact ofheadache in Europe: principal results of the Eurolight project. J Headache Pain 15:31PubMedCentralCrossRefPubMed
13.
go back to reference Vinding GR, Zeeberg P, Lyngberg A et al. (2007) The burden of headache in a patient population from a specialized headache centre. Cephalalgia 27(3):263–270CrossRefPubMed Vinding GR, Zeeberg P, Lyngberg A et al. (2007) The burden of headache in a patient population from a specialized headache centre. Cephalalgia 27(3):263–270CrossRefPubMed
14.
go back to reference Rapoport A, Stang P, Gutterman DL, Cady R, Markley H, Weeks R et al. (1996) Analgesic rebound headache in clinical practice: data from a physician survey. Headache 36(1):14–19CrossRefPubMed Rapoport A, Stang P, Gutterman DL, Cady R, Markley H, Weeks R et al. (1996) Analgesic rebound headache in clinical practice: data from a physician survey. Headache 36(1):14–19CrossRefPubMed
15.
go back to reference Nogales-Gaete J (1992) Jaqueca por dependencia de tartrato de ergotamina. Rev Med Chile 120(7):797–799PubMed Nogales-Gaete J (1992) Jaqueca por dependencia de tartrato de ergotamina. Rev Med Chile 120(7):797–799PubMed
16.
go back to reference Castillo J, Muñoz P, Guitera V et al. (1999) Epidemiology of chronic daily headache in general population. Headache 39(3):190–196CrossRefPubMed Castillo J, Muñoz P, Guitera V et al. (1999) Epidemiology of chronic daily headache in general population. Headache 39(3):190–196CrossRefPubMed
17.
go back to reference Bendtsen L, Munksgaard S, Tassorelli C et al. (2014) Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia 34(6):426–433CrossRefPubMed Bendtsen L, Munksgaard S, Tassorelli C et al. (2014) Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia 34(6):426–433CrossRefPubMed
18.
go back to reference Tassorelli C, Jensen R, Allena M et al. (2014) A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. Cephalalgia 34(9):645–655CrossRefPubMed Tassorelli C, Jensen R, Allena M et al. (2014) A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. Cephalalgia 34(9):645–655CrossRefPubMed
19.
go back to reference Headache Classification Committee of the International Headache Society (IHS) (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33:629–808CrossRef Headache Classification Committee of the International Headache Society (IHS) (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33:629–808CrossRef
20.
go back to reference Headache Classification Committee of International Headache Society (2004) The International Classification of Headache Disorders. 2nd ed. Cephalalgia 24(Suppl 1):1–160 Headache Classification Committee of International Headache Society (2004) The International Classification of Headache Disorders. 2nd ed. Cephalalgia 24(Suppl 1):1–160
21.
go back to reference Headache Classification Committee (2006) New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26:742–746CrossRef Headache Classification Committee (2006) New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26:742–746CrossRef
22.
go back to reference Jonsson P, Linde M, Hensing G, Hedenrud T (2012) Sociodemographic differences inmedication use, health-care contacts and sickness absence among individuals with medication-overuse headache. J Headache Pain 13(4):281–290PubMedCentralCrossRefPubMed Jonsson P, Linde M, Hensing G, Hedenrud T (2012) Sociodemographic differences inmedication use, health-care contacts and sickness absence among individuals with medication-overuse headache. J Headache Pain 13(4):281–290PubMedCentralCrossRefPubMed
23.
go back to reference Diener HC, Dahlöf CGH (1999) Headache associated with chronic use of substances. In: Oleson J, Tfelt-Hansen P, Welch KMA (eds) The headaches, 2nd edn. Lippincott, Philadelphia, pp 871–878 Diener HC, Dahlöf CGH (1999) Headache associated with chronic use of substances. In: Oleson J, Tfelt-Hansen P, Welch KMA (eds) The headaches, 2nd edn. Lippincott, Philadelphia, pp 871–878
24.
go back to reference Atasoy HT, Atasoy N, Unal AE, Emre U, Sumer M (2005) Psychiatric comorbidity inmedication overuse headache patients with pre-existing headache type of episodic tension-type headache. Eur J Pain 9(3):285–291CrossRefPubMed Atasoy HT, Atasoy N, Unal AE, Emre U, Sumer M (2005) Psychiatric comorbidity inmedication overuse headache patients with pre-existing headache type of episodic tension-type headache. Eur J Pain 9(3):285–291CrossRefPubMed
Metadata
Title
Clinical and Demographical Characteristics of Patients with Medication Overuse Headache in Argentina and Chile: Analysis of the Latin American Section of COMOESTAS Project
Authors
Beatriz Shand
Maria Teresa Goicochea
Raul Valenzuela
Ricardo Fadic
Rigmor Jensen
Cristina Tassorelli
Giuseppe Nappi
 the COMOESTAS CONSORTIUM
Publication date
01-12-2015
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 1/2015
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/s10194-015-0561-1

Other articles of this Issue 1/2015

The Journal of Headache and Pain 1/2015 Go to the issue